The article discusses drugs for treatment of sickle cell disease and investment by the pharmaceutical industry in disease treatment. Topics discussed include drug hydroxyurea, bone marrow transplants and drug Aes-103 for disease treatment acquired by pharmaceutical company Baxter International. Other topics include vaso-occulusive crisis, research for sickle cell treatment and drug MST-188.